SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Rheumatology and Clinical Immunology

[Return To Index page]
photo Chester V. Oddis, MD

Professor of Medicine

Associate Director, Rheumatology Fellowship Training Program

Email: cvo5@pitt.edu

Phone: 412-383-8861

Contact
Office: Division of Rheumatology and Clinical Immunology
S705 BST, 3500 Terrace Street
Pittsburgh, PA 15261
 
Phone: 412-383-8861
Fax: 412-383-8864
E-mail: cvo5@pitt.edu
Administrative Assistant:
Margie Jones
Address: 3500 Terrace Street, S705A BST
Pittsburgh, PA 15261
Email: jonema2@pitt.edu
Phone: 412-383-8861
Education and Training
Education
BS, University of Pittsburgh, 1976
M.D., Pennsylvania State University College of Medicine, 1980
Training
Internship, Pennsylvania State University College of Medicine, 1884
Residency, University Hosiptal, Pennsylvania State University, 1984
Fellowship, University of Pittsburgh School of Medicine, 1987
Research Interest
Dr. Oddis has been involved in myositis research for over 30 years with a longstanding interest in the epidemiology, clinical features, autoantibody correlations and treatment of myositis. As Director of the Myositis Center at the University of Pittsburgh, he supervises and manages one of the world’s largest clinically- and serologically-defined, longitudinal myositis databases which includes over 1000 patients with adult polymyositis, adult dermatomyositis, and overlap myositis disorders. He was the Principal Investigator on the RIM (Ritubimab in Myositis) Trial, the first multicenter clinical trial in myositis funded by the National Institutes of Health (N01 AR042273) and the largest clinical trial ever completed in myositis enrolling 200 subjects from 20 adult and 11 pediatric national and international centers. He collaborates with many national and international myositis investigators and has been involved with task forces developing clinical trial guidelines for both myositis as well as connective tissue disease associated interstitial lung disease (ILD). In 2008 he developed the Rheumatic Disease Data Management System (RDMS) enabling myositits investigators to link disease activity and damage measures with clinical, laboratory, serologic and experimental data over time. RDMS is web-based allowing real-time entry of clinical data and includes a robust specimen tracking system leading to a valuable specimen repositry. Dr. Oddis has written extensively on the diagnosis and management of patients with myositis including use of novel immunosuppressive agents such as tacrolimus.
Clinical Interest
My primary clinical interest is in treating idiopathic inflammatory myopathy.
Educational Interest
Dr. Oddis serves as the Associate Director of the Fellowship Training Program at the University of Pittsburgh.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Moghadam-Kia, S., Aggarwal, R., Oddis, C.V. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Review in Clinical Immunology. 2015; 11(11): 1265-1275.
Reed, A.M., Crowson, C.S., Hein, M., de Padilla, C.L., Olazagasti, J.M., Aggarwal, R., Ascherman, D.P., Levesque, M.C., Oddis, C.V. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskeletal Disorders. 2015; 16(257).
Moghadam-Kia, S., Oddis, C.V., Sato, S., Kuwana, M., Aggarwal, R. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. Arthritis Care & Research. 2016; 68(5): 689-694.
Lopez De Padilla, C.M., Crowson, C.S., Hein, M.S., Strausbauch, M.A., Aggarwal, R., Levesque, M.C., Ascherman, D.P., Oddis, C.V., Reed, A.M. Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. Clinical Experimental Rheumatology. 2015; 33(5): 655-663.
Loganathan, P., Oddis, C.V., Aggarwal, R. Immune-mediated statin myopathy. Expert Review of Clinical Immunology. 2015; 12(1): 33-38.
El-Dokla, A.M., Aggarwal, R., Oddis, C.V., Ali, S.T., Lacomis, D. Histopathologic Findings in 5 Patients With Hypomyopathic Dermatomyositis: The Importance of MHC-1 Expression on Myofibers. Journal of Clinical Neuromuscular Disease. 2015; 17(2): 52-58.
Moghadam-Kia, S., Oddis, C.V., Aggarwal, R. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. Clinical Reviews in Allergy & Immunology. 2016.
Moghadam-Kia, S., Oddis, C.V., Aggarwal, R. Approach to asymptomatic creatine kinase elevation. Cleveland Clinic Journal of Medicine. 2016; 83(1): 37-42.
Oddis, C.V. Update on the pharmacological treatment of adult myositis. Journal of Internal Medicine. 2016; 280(1): 63-74.
Aggarwal, R., Oddis, C. V., Goudeau, D., Koontz, D., Qi, Z., Reed, A. M., Ascherman, D. P., Levesque, M. C. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology. 2016; 55(6): 991.
Sponsored Research/Activities
Title: Environmental Risk Factors for the Antisynthetase Syndrome Protocol (MYORISK)
Role: Principal Investigator
Funding Agency: Social and Scientific Systems, Inc.
Grant Number: N01
Start Year: 2016
End Year: 2017
Title: Autoimmunity Center of Excellence Clinical Research Program: Rituximab for Treatment of SSc-PAH (ASC01)-Mechanistic
Role: Principal Investigator
Funding Agency: University of California - San Francisco
Grant Number: UM1 AI110498
Start Year: 2016
End Year: 2017
Title: Studies of The Natural History and Pathogenesis of Autoimmune and Connective Tissue Diseases (MTA)
Role: Principal Investigator
Funding Agency: National Institute of Environmental Health Sciences
Start Year: 2015
End Year: 2020
Title: Analysis and Cleansing of Osteoarthritis Initiative (OAI) and the Pivotal Osteoarthritis MRI Analyses (POMA) Data
Role: Principal Investigator
Funding Agency: University of Arizona
Start Year: 2015
End Year: 2016
Title: Tocilzumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Role: Principal Investigator
Funding Agency: Genentech, Inc.
Start Year: 2014
End Year: 2017
Title: Rituximab Therapy in Patients with IPF
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL119960
Start Year: 2013
End Year: 2015
Title: Collecting DNA Samples and Data for Myositis Genetics Consortium
Role: Principal Investigator
Funding Agency: National Institute of Environmental Health Sciences
Start Year: 2012
End Year: 2019
Title: Environmental Risk Factors for the Antisynthetase Syndrome Protocol (MYORISK)
Role: Principal Investigator
Funding Agency: SRA international, Inc./National Institute of Environmental Health Sciences
Grant Number: N01
Start Year: 2011
End Year: 2015
Title: Mechanisms of B Cell Responses in Autoimmune Disease, A Randomized, Double-blind Placebo-Controlled Phase II Multicenter Trial of Monoclonal Antibody to CD20 (Rituximab)- (LAB)
Role: Principal Investigator
Funding Agency: Duke University/National Institute of Allergy & Infectious Diseases
Grant Number: U19 AI056363
Start Year: 2010
End Year: 2016
Title: Mechanisms of Response and Relapse in Rituximab-Treated Myostitis Patients
Role: Principal Investigator
Funding Agency: National Institute of Arthristis, Muscoskel, & Skin Disease
Grant Number: R01 AR061298
Start Year: 2010
End Year: 2014
Title: Peripheral Blood Biomarkers of RA-associated Interstitial Lung Disease
Role: Principal Investigator
Funding Agency: University of Miami
Start Year: 2010
End Year: 2013
Title: Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Polymyositis (PM)
Role: Principal Investigator
Funding Agency: Genentech, Inc.
Start Year: 2006
End Year: 2017
Title: Molecular Characterization of Fc Receptor Biology Index in Myositis Patients
Role: Co-Investigator
Funding Agency: Momenta Pharmaceuticals, Inc.
Grant Number: RES
Start Year: 2016
End Year: 2017
Title: Novel Outcome Measures in Adult Myositis Using a Physical Activity Monitor and the PROMIS Physical Function Assessments
Role: Co-Investigator
Funding Agency: Myositis Association
Start Year: 2015
End Year: 2017
Title: Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis (Clinical Trial)
Role: Co-Investigator
Funding Agency: Questcor Pharmaceuticals, Inc.
Start Year: 2013
End Year: 2016